Back to Search Start Over

Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.

Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.

Authors :
Cella CA
Minucci S
Spada F
Galdy S
Elgendy M
Ravenda PS
Zampino MG
Murgioni S
Fazio N
Source :
Cancer treatment reviews [Cancer Treat Rev] 2015 Nov; Vol. 41 (9), pp. 754-60. Date of Electronic Publication: 2015 Jun 28.
Publication Year :
2015

Abstract

After years of limited progress in the treatment of neuroendocrine neoplasms (NENs), an increasing number of therapeutic targets have recently emerged as potential tools to improve disease outcome. The mammalian target of rapamycin (mTOR) pathway and vascular endothelial growth factor (VEGF) signalling are implicated in the regulation of cell growth, proliferation, neo-angiogenesis and tumour cell spread. Their combined blockade, in a simultaneous or sequential strategy, represents an intriguing biological rationale to overcome the onset of resistance mechanisms. However, is becoming increasingly imperative to find the optimal sequential strategy according to the best toxicity profile, and also to identify predictive biomarkers. We will provide an overview of the pre-clinical and clinical data relating to mTOR pathway/VEGF signalling as a potential targets of treatment in NENs.<br /> (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1532-1967
Volume :
41
Issue :
9
Database :
MEDLINE
Journal :
Cancer treatment reviews
Publication Type :
Academic Journal
Accession number :
26142874
Full Text :
https://doi.org/10.1016/j.ctrv.2015.06.008